Research programme: TRPM8 channel inhibitors - RaQualia

Drug Profile

Research programme: TRPM8 channel inhibitors - RaQualia

Alternative Names: CMR-1 anatgonists - RaQualia; RQ-00434739

Latest Information Update: 25 Nov 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator RaQualia Pharma
  • Class Small molecules
  • Mechanism of Action TRPM8 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neuropathic pain; Pain
  • No development reported Inflammation

Most Recent Events

  • 26 Sep 2016 Pharmacodynamics data from a preclinical study presented at the 16th World Congress on Pain (WCP-2016)
  • 02 Sep 2016 Preclinical trials in Neuropathic pain in Japan (unspecified route)
  • 20 Jul 2016 Early research in Neuropathic pain in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top